Madrigal Pharmaceuticals, Inc. (MDGL) has a MoatMap StockRank of 44/100 based on Quality (39/100), Value (35/100), and Momentum (56/100) factor scores. The current signal is HOLD. Madrigal is a development-stage biotech transitioning to commercialization. While its NASH drug has high potential, it lacks the established cash flows, high ROIC, and predictable reinvestment runway required by both Terry Smith and Warren Buffett.
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for non-alcoholic steatohepatitis (NASH) and other liver diseases. Its lead product candidate, resmetirom, targets the thyroid hormone receptor beta, addressing an area with significant unmet medical need and no approved treatments. The company's competitive edge lies in its potential first-in-class NASH therapy, which could capture a substantial share of this growing market if approved, offering a significant opportunity in a challenging disease area.
| Price | $475.92 |
| Market Cap | $11.9B |
| P/E (Forward) | 39.81 |
| Price/Book | 20.90 |
| Return on Equity | -49.3% |
| Return on Invested Capital | -28.0% |
| Debt/Equity | 63.91 |
| Gross Margin | 93.1% |
| Operating Margin | -29.8% |
| Revenue Growth | 126.8% |
| Free Cash Flow | $-156M |
Madrigal Pharmaceuticals, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).